葡萄糖共载体-2 抑制剂 恩帕格利弗洛辛 增加抗氧化能力,改善糖尿病大鼠的功能
Habib Yaribeygi1, Mohammad Amin Hemmati2, Fatemeh Nasimi1
1Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.
Journal of clinical medicine
|June 10, 2023
概括
在糖尿病大鼠中,empagliflozin治疗改善了功能,并减少了氧化应激. 这表明SGLT2抑制剂可能会为糖尿病病提供超出血糖控制的额外益处.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病病症涉及氧化压力作为一个关键的病理机制.
- -葡萄糖共运输体2 (SGLT2) 抑制剂是抗糖尿病药物的一类,具有潜在的附加作用.
- 恩帕格利弗洛辛是一种SGLT2抑制剂,研究其对糖尿病中氧化应激和功能的影响.
研究的目的:
- 评估empagliflozin对氧化应激标志物和糖尿病大鼠模型中的功能的影响.
- 为了确定empagliflozin是否可以减轻糖尿病引起的损伤.
主要方法:
- 雄性Wistar大鼠被分为控制,控制治疗,糖尿病和糖尿病治疗组 (n=8).
- 糖尿病被诱导使用链毒素;治疗组接受了empagliflozin (20 mg/kg/day) 5周.
- 测量了血清尿素,尿酸,肌和组织氧化应激标志物 (MDA,GLT,CAT,SOD).
主要成果:
- 糖尿病显著增加了血清尿素,尿酸和肌,同时降低了抗氧化酶 (CAT,SOD) 和谷氨 (GLT),并增加了甲 (MDA).
- 恩帕格利弗洛辛治疗显著降低了血清尿素,尿酸和肌素.
- 恩帕格利弗洛辛治疗增加了抗氧化能力 (CAT,SOD,GLT) 和减少了氧化损伤 (MDA).
结论:
- 失控的糖尿病会导致通过减少抗氧化剂防御和增加氧化应激导致功能衰竭.
- 恩帕格利弗洛辛证明了除降低葡萄糖之外的潜在益处,包括逆转氧化应激和改善糖尿病病中的功能.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
01:23Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
01:06Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
01:27Glucose Transporters
23.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.4K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
218
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
218